Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides

Nura O. Elmagbari, Richard D. Egleton, Michael M. Palian, John J. Lowery, Wendi R. Schmid, Peg Davis, Edita Navratilova, Muthu Dhanasekaran, Charles M. Keyari, Henry I. Yamamura, Frank Porreca, Victor J Hruby, Robin L Polt, Edward J. Bilsky

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Development of opioid peptides as therapeutic agents has historically been limited due to pharmacokinetic issues including stability and blood-brain barrier (BBB) permeability. Glycosylation of opioid peptides can increase peptide serum stability and BBB penetration. To further define the requirements for optimizing in vivo antinociceptive potency following intravenous administration, we synthesized a series of enkephalin-based glycopeptides using solid phase 9-fluorenylmethyloxy carbamate methods. The compounds differed in the sixth and subsequent amino acid residues (Ser or Thr) and in the attached carbohydrate moiety. In vitro binding and functional smooth muscle bioassays indicated that the addition of mono- or disaccharides did not significantly affect the opioid receptor affinity or agonist activity of the glycopeptides compared with their unglycosylated parent peptides. All of the glycopeptides tested produced potent antinociceptive effects in male ICR mice following intracerebroventricular injection in the 55°C tail-flick test. The calculated A50 values for the Ser/Thr and monosaccharide combinations were all very similar with values ranging from 0.02 to 0.09 nmol. Selected compounds were administered to mice intravenously and tested for antinociception to indirectly assess serum stability and BBB penetration. All compounds tested produced full antinociceptive effects with calculated A50 values ranging from 2.2 to 46.4 μmol/kg with the disaccharides having potencies that equaled or exceeded that of morphine on a micromoles per kilogram basis. Substitution of a trisaccharide or bis- and tris-monosaccharides resulted in a decrease in antinociceptive potency. These results provide additional support for the utility of glycosylation to increase central nervous system bioavailability of small peptides and compliment our ongoing stability and blood-brain barrier penetration studies.

Original languageEnglish (US)
Pages (from-to)290-297
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume311
Issue number1
DOIs
StatePublished - Oct 2004

Fingerprint

Glycopeptides
Monosaccharides
Enkephalins
Blood-Brain Barrier
Opioid Analgesics
Opioid Peptides
Disaccharides
Glycosylation
Peptides
Trisaccharides
Inbred ICR Mouse
Carbamates
Opioid Receptors
Serum
Biological Assay
Intravenous Administration
Morphine
Biological Availability
Smooth Muscle
Tail

ASJC Scopus subject areas

  • Pharmacology

Cite this

Elmagbari, N. O., Egleton, R. D., Palian, M. M., Lowery, J. J., Schmid, W. R., Davis, P., ... Bilsky, E. J. (2004). Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. Journal of Pharmacology and Experimental Therapeutics, 311(1), 290-297. https://doi.org/10.1124/jpet.104.069393

Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. / Elmagbari, Nura O.; Egleton, Richard D.; Palian, Michael M.; Lowery, John J.; Schmid, Wendi R.; Davis, Peg; Navratilova, Edita; Dhanasekaran, Muthu; Keyari, Charles M.; Yamamura, Henry I.; Porreca, Frank; Hruby, Victor J; Polt, Robin L; Bilsky, Edward J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 311, No. 1, 10.2004, p. 290-297.

Research output: Contribution to journalArticle

Elmagbari, NO, Egleton, RD, Palian, MM, Lowery, JJ, Schmid, WR, Davis, P, Navratilova, E, Dhanasekaran, M, Keyari, CM, Yamamura, HI, Porreca, F, Hruby, VJ, Polt, RL & Bilsky, EJ 2004, 'Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides', Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 1, pp. 290-297. https://doi.org/10.1124/jpet.104.069393
Elmagbari, Nura O. ; Egleton, Richard D. ; Palian, Michael M. ; Lowery, John J. ; Schmid, Wendi R. ; Davis, Peg ; Navratilova, Edita ; Dhanasekaran, Muthu ; Keyari, Charles M. ; Yamamura, Henry I. ; Porreca, Frank ; Hruby, Victor J ; Polt, Robin L ; Bilsky, Edward J. / Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. In: Journal of Pharmacology and Experimental Therapeutics. 2004 ; Vol. 311, No. 1. pp. 290-297.
@article{3228d7234fbd44a485b2cec4b9dd589f,
title = "Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides",
abstract = "Development of opioid peptides as therapeutic agents has historically been limited due to pharmacokinetic issues including stability and blood-brain barrier (BBB) permeability. Glycosylation of opioid peptides can increase peptide serum stability and BBB penetration. To further define the requirements for optimizing in vivo antinociceptive potency following intravenous administration, we synthesized a series of enkephalin-based glycopeptides using solid phase 9-fluorenylmethyloxy carbamate methods. The compounds differed in the sixth and subsequent amino acid residues (Ser or Thr) and in the attached carbohydrate moiety. In vitro binding and functional smooth muscle bioassays indicated that the addition of mono- or disaccharides did not significantly affect the opioid receptor affinity or agonist activity of the glycopeptides compared with their unglycosylated parent peptides. All of the glycopeptides tested produced potent antinociceptive effects in male ICR mice following intracerebroventricular injection in the 55°C tail-flick test. The calculated A50 values for the Ser/Thr and monosaccharide combinations were all very similar with values ranging from 0.02 to 0.09 nmol. Selected compounds were administered to mice intravenously and tested for antinociception to indirectly assess serum stability and BBB penetration. All compounds tested produced full antinociceptive effects with calculated A50 values ranging from 2.2 to 46.4 μmol/kg with the disaccharides having potencies that equaled or exceeded that of morphine on a micromoles per kilogram basis. Substitution of a trisaccharide or bis- and tris-monosaccharides resulted in a decrease in antinociceptive potency. These results provide additional support for the utility of glycosylation to increase central nervous system bioavailability of small peptides and compliment our ongoing stability and blood-brain barrier penetration studies.",
author = "Elmagbari, {Nura O.} and Egleton, {Richard D.} and Palian, {Michael M.} and Lowery, {John J.} and Schmid, {Wendi R.} and Peg Davis and Edita Navratilova and Muthu Dhanasekaran and Keyari, {Charles M.} and Yamamura, {Henry I.} and Frank Porreca and Hruby, {Victor J} and Polt, {Robin L} and Bilsky, {Edward J.}",
year = "2004",
month = "10",
doi = "10.1124/jpet.104.069393",
language = "English (US)",
volume = "311",
pages = "290--297",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides

AU - Elmagbari, Nura O.

AU - Egleton, Richard D.

AU - Palian, Michael M.

AU - Lowery, John J.

AU - Schmid, Wendi R.

AU - Davis, Peg

AU - Navratilova, Edita

AU - Dhanasekaran, Muthu

AU - Keyari, Charles M.

AU - Yamamura, Henry I.

AU - Porreca, Frank

AU - Hruby, Victor J

AU - Polt, Robin L

AU - Bilsky, Edward J.

PY - 2004/10

Y1 - 2004/10

N2 - Development of opioid peptides as therapeutic agents has historically been limited due to pharmacokinetic issues including stability and blood-brain barrier (BBB) permeability. Glycosylation of opioid peptides can increase peptide serum stability and BBB penetration. To further define the requirements for optimizing in vivo antinociceptive potency following intravenous administration, we synthesized a series of enkephalin-based glycopeptides using solid phase 9-fluorenylmethyloxy carbamate methods. The compounds differed in the sixth and subsequent amino acid residues (Ser or Thr) and in the attached carbohydrate moiety. In vitro binding and functional smooth muscle bioassays indicated that the addition of mono- or disaccharides did not significantly affect the opioid receptor affinity or agonist activity of the glycopeptides compared with their unglycosylated parent peptides. All of the glycopeptides tested produced potent antinociceptive effects in male ICR mice following intracerebroventricular injection in the 55°C tail-flick test. The calculated A50 values for the Ser/Thr and monosaccharide combinations were all very similar with values ranging from 0.02 to 0.09 nmol. Selected compounds were administered to mice intravenously and tested for antinociception to indirectly assess serum stability and BBB penetration. All compounds tested produced full antinociceptive effects with calculated A50 values ranging from 2.2 to 46.4 μmol/kg with the disaccharides having potencies that equaled or exceeded that of morphine on a micromoles per kilogram basis. Substitution of a trisaccharide or bis- and tris-monosaccharides resulted in a decrease in antinociceptive potency. These results provide additional support for the utility of glycosylation to increase central nervous system bioavailability of small peptides and compliment our ongoing stability and blood-brain barrier penetration studies.

AB - Development of opioid peptides as therapeutic agents has historically been limited due to pharmacokinetic issues including stability and blood-brain barrier (BBB) permeability. Glycosylation of opioid peptides can increase peptide serum stability and BBB penetration. To further define the requirements for optimizing in vivo antinociceptive potency following intravenous administration, we synthesized a series of enkephalin-based glycopeptides using solid phase 9-fluorenylmethyloxy carbamate methods. The compounds differed in the sixth and subsequent amino acid residues (Ser or Thr) and in the attached carbohydrate moiety. In vitro binding and functional smooth muscle bioassays indicated that the addition of mono- or disaccharides did not significantly affect the opioid receptor affinity or agonist activity of the glycopeptides compared with their unglycosylated parent peptides. All of the glycopeptides tested produced potent antinociceptive effects in male ICR mice following intracerebroventricular injection in the 55°C tail-flick test. The calculated A50 values for the Ser/Thr and monosaccharide combinations were all very similar with values ranging from 0.02 to 0.09 nmol. Selected compounds were administered to mice intravenously and tested for antinociception to indirectly assess serum stability and BBB penetration. All compounds tested produced full antinociceptive effects with calculated A50 values ranging from 2.2 to 46.4 μmol/kg with the disaccharides having potencies that equaled or exceeded that of morphine on a micromoles per kilogram basis. Substitution of a trisaccharide or bis- and tris-monosaccharides resulted in a decrease in antinociceptive potency. These results provide additional support for the utility of glycosylation to increase central nervous system bioavailability of small peptides and compliment our ongoing stability and blood-brain barrier penetration studies.

UR - http://www.scopus.com/inward/record.url?scp=4644258417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644258417&partnerID=8YFLogxK

U2 - 10.1124/jpet.104.069393

DO - 10.1124/jpet.104.069393

M3 - Article

C2 - 15166257

AN - SCOPUS:4644258417

VL - 311

SP - 290

EP - 297

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -